

Occupational Health and Safety Assessment Series (OHSAS) certificate

**ALMIRALL CERTIFIES ITS OCCUPATIONAL RISK PREVENTION MANAGEMENT SYSTEM
SURPASSING CURRENT LEGISLATION IN SPAIN**

- The certifying body of TÜVRheinland in Spain, TÜV Internacional Grupo TÜV Rheinland, S.L. has awarded Almirall the prestigious certification OHSAS 18001 after an exhaustive assessment process that certifies application of quality standards over and above current legislation in Spain.
- Almirall is one of the first pharmaceutical companies in Spain to receive this national and international recognition.

Barcelona, 30 March 2007.- Laboratorios Almirall, S.A. (Almirall), a Spanish independent pharmaceutical company, has been awarded the prestigious TÜVRheinland certificate which attests the conformity of its Occupational Risk Prevention Management System to the international standard OHSAS 18001. After a thorough assessment involving all centres and activities TÜV Internacional attests that Almirall is consistently applying occupational health and safety criteria in excess of those required by current legislation standards in Spain.

OHSAS 18001 (*Occupational Health and Safety Assessment Series*) is an Occupational Risk Prevention Management standard developed by an international consortium of standardisation and certification bodies. The standard was published in 1999 by the BSI (*British Standards Institution*). The OHSAS 18001 sets out the structural elements of an Occupational Risk Prevention Management System to review, manage and improve monitoring of risks in the workplace. The standard includes a series of controls and requirements that help the company comply with applicable legislation and a continuous improvement process.

TÜVRheinland is an international group, leader in inspection services, environmental protection, certification of management systems and of safety and quality of products, with over 20 years' experience in Spain. The certification awarded to Almirall is valid for three years. During this time several annual follow-up audits will be performed followed by a renewal audit.

About Almirall

Almirall, a leading company committed to health, is a consolidated international pharmaceutical company that researches, develops and commercialises its own R&D and licensed drugs with the aim of improving people's health and quality of life.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD, psoriasis, rheumatoid arthritis and multiple sclerosis.

Almirall is currently present in over 80 countries. The company has direct presence in Europe and Latin America via affiliates in France, Germany, Italy, Portugal, Belgium and Mexico.

For further information, please, visit the website at: www.almirall.es

Further information:

Ketchum/SEIS

Victoria Hernández / Carla Cudós

Victoria.hernandez@ketchum.com

carla.cudos@ketchum.com

Tel.: 91 788 32 00 - Fax: 91 788 32 99

NOTE

This document is a press release and not a prospectus. Investors should not therefore acquire or apply for any shares or other securities mentioned herein without having previously consulted the information contained within the official prospectus relating to the flotation of company shares on the Spanish stock exchanges, which will be published by the company in due course. Copies of the prospectus will be available at the registered offices of the Company once they have been published.

This document should in no way be construed as an offer or invitation to treat, nor does it represent an offer to buy or subscribe to shares in the Company. Likewise, the contents of this document and the fact that it has been distributed must not be used as, or form the basis for, any kind of contract or decision to invest and do not constitute any recommendation as regards the securities of the Company.

This communication is intended solely for people living outside the United Kingdom and may not be used by anybody living within that country.

The information contained herein does not constitute an offer of securities in the United States. Offers and sales of securities in the United States may not be made absent registration under the U.S. Securities Act of 1933, as amended, or an applicable exemption therefrom. This document does not solicit money, securities or any other type of consideration, and, if any money, securities or other type of consideration is sent in response hereto, it will not be accepted.

Finally, neither this document nor any copy thereof may be taken or transmitted to the United States of America, Canada, Australia or Japan or be distributed, either directly or indirectly, in the United States of America, Canada, Australia or Japan or given to residents of any of these countries.